Clinical Trials Directory

Trials / Completed

CompletedNCT02616822

Effects of Trans-Resveratrol in Endothelial Function in Hypertensive Patients

Acute Effects Of Trans-Resveratrol in Endothelial Function in Treated Hypertensive Patients

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Hospital Universitario Pedro Ernesto · Academic / Other
Sex
All
Age
45 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Arterial Hypertension (HBP) has a high prevalence and low rates of control, is considered a major modifiable risk factors and one of the most important public health problems. Mortality from cardiovascular disease increases progressively with increasing blood pressure (BP) in a linear, continuous and independent. The pathophysiological mechanisms involved in the pathogenesis of hypertension exhibit metabolic abnormalities, which are related to endothelial dysfunction. Resveratrol, a polyphenol stilbene derived from various species of plants, but in our food, mainly present in red wine and grapes, has shown protective effects in cardiovascular diseases, such as preventing the damage caused by oxidative stress, decreased plasma lipids with inhibiting the formation of atherosclerotic plaque; protective effect of vascular endothelium, with increased release of nitric oxide and decreased production of free radicals in animal models, but human studies are limited and insufficient to clarify the possible effects of trans-resveratrol (biologically active form) on endothelial function, blood pressure and central aortic pressure in treated hypertensive individuals.The aim of this study is to evaluate the acute effects of trans-resveratrol supplementation on endothelial function in treated hypertensive patients.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTTrans-resveratrolUsed for trans-resveratrol substance 300 mg single dose
OTHERPlaceboUsed for placebo substance single dose

Timeline

Start date
2013-01-01
Primary completion
2015-09-01
Completion
2015-09-01
First posted
2015-11-30
Last updated
2015-11-30

Source: ClinicalTrials.gov record NCT02616822. Inclusion in this directory is not an endorsement.